Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained from the subject/ from the parent/ guardian of the subject.~* Subjects who completed the full course of primary vaccination.~Exclusion Criteria:~* Immunosuppression caused by the administration of parenteral steroids or chemotherapy.~* Any confirmed or suspected human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Henogen Hepatitis B vaccine for uremic patients
- 2 (Type: ACTIVE_COMPARATOR): Fendrix hepatitis B vaccine for uremic patients

Based on this trial design, predict the completion outcome and termination type (if applicable).